E6011
Sponsors
Eisai Co., Ltd., Eisai Inc., EA Pharma Co., Ltd.
Conditions
Arthritis, RheumatoidCrohn's DiseaseHealthyHealthy Male VolunteersPrimary Biliary CholangitisRheumatoid Arthritis
Phase 1
A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)
CompletedNCT01731275
Start: 2012-08-31End: 2013-08-31Updated: 2014-02-14
A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects
CompletedNCT02146261
Start: 2013-09-30End: 2014-04-30Updated: 2014-10-22
A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis
CompletedNCT02196558
Start: 2014-05-26End: 2017-07-13Updated: 2020-08-13
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
WithdrawnNCT02249078
Start: 2014-12-31End: 2016-04-30Updated: 2015-11-05
Phase 2
A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
CompletedNCT02960438
Start: 2016-10-20End: 2019-09-17Updated: 2021-06-21
A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
CompletedNCT02960490
Start: 2016-11-26End: 2019-11-25Updated: 2021-08-23
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
TerminatedNCT03092765
Start: 2017-05-29End: 2018-10-22Updated: 2019-01-04
A Study of E6011 in Participants With Active Crohn's Disease
CompletedNCT03733314
Start: 2019-04-25End: 2024-04-03Updated: 2025-04-02